In the future, it will be interesting to address whether targeting the ARRDC3-PAR1–associated inflammatory cellular networks and/or molecular pathways described here in the context of H. pylori infection could improve the outcome of the infection, which may lead to the application of novel pharmacological approaches to H. pylori–associated gastritis. Here, ARRDC3 is linked to gastritis.